Take two for QRxPharma
Friday, 27 February, 2009
Sydney-based QRxPharma has begun a comparative pilot study to test the efficacy and safety of its MoxDuo immediate release analgesic in patients with post-operative pain.
Data from the three-arm study will be used to establish the optimal dose regimen and in the design of the company’s planned Phase III trial in patients following total knee replacement surgery.
The study hopes to enrol 45 patients at three US clinical research sites. Each group of patients will be treated every four to six hours over a 48-hour period.
The study will compare the analgesic efficacy and safety profile of MoxDuo against control groups receiving Percocet, and against patient controlled analgesia.
MoxDuo consists of a fixed ratio of morphine and oxycodone. It is intended for the treatment of moderate to severe pain.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
